Related by context. All words. (Click for frequent words.) 78 Phase III Clinical Trial 78 Acute Myocardial Infarction 77 Prospective Randomized 77 Oral Fingolimod 76 Relapsing Multiple Sclerosis 76 Meets Primary Endpoint 76 Improves Outcomes 76 Patients Treated 76 Acute Coronary Syndromes 76 Prolongs Survival 75 Pulmonary Arterial Hypertension 75 Patients Undergoing 75 Left Ventricular 75 Randomized Clinical Trial 75 Elderly Patients 75 Severe Sepsis 75 Pivotal Trial 75 Long Term Efficacy 74 Overactive Bladder 74 Pegylated Liposomal Doxorubicin 74 Phase III Trial 74 Clinical Outcome 74 Newly Diagnosed Multiple Myeloma 74 Radiofrequency Ablation 74 Randomized Evaluation 74 Renal Cell Carcinoma 74 Advanced Melanoma 74 Chronic Heart Failure 74 Phase 2b Clinical Trial 74 Improves Survival 74 Tyrosine Kinase Inhibitor 74 Ranolazine 74 Combination Treatment 73 Carotid Stenting 73 Patients Treated With 73 Pooled Analysis 73 Ischemic Stroke 73 Catheter Ablation 73 Antiviral Activity 73 Valsartan 73 Thrombolysis 73 Metastatic Prostate Cancer 73 Subgroup Analysis 73 JAK Inhibitor 73 Venous Thromboembolism 73 Phase 2b Study 73 Myelodysplastic Syndromes 73 Nebulized 73 fosbretabulin 73 Clinical Trial Results 73 Demonstrates Positive 73 Phase IIb Trial 73 Demonstrates Efficacy 73 Complicated Skin 73 Cardiogenic Shock 73 Tiotropium 73 Heart Failure Patients 73 Percutaneous Coronary Intervention 73 Drug Eluting Stents 73 Is Well Tolerated 73 Acute Heart Failure 73 Well Tolerated 72 Autologous Stem Cell Transplantation 72 Survival Benefit 72 Novel Oral 72 Metastatic Colorectal Cancer 72 Clinical Trial Evaluating 72 Rheumatoid Arthritis Patients 72 Disease Progression 72 Dose Escalation 72 Abciximab 72 Platelet Inhibition 72 Chemoradiation 72 Controlled Trial 72 Aortic Stenosis 72 Glatiramer Acetate 72 Infarct 72 Placebo Controlled Trial 72 ST Elevation Myocardial 72 Study Evaluating 72 See CLINICAL PHARMACOLOGY 72 Pharmacokinetic Study 72 Dual Antiplatelet Therapy 72 Unfractionated Heparin 72 II Clinical Trial 72 Enzyme Replacement Therapy 72 Adjuvant Therapy 72 Pharmacodynamics 72 Meta Analysis 72 Safinamide 72 Hormone Refractory Prostate Cancer 72 Hepatitis C Genotype 72 Cardiotoxicity 72 Unstable Angina 72 Treating Chronic 72 Controlled Study 72 Monotherapy 72 Stent Restenosis 71 Antitumor Activity 71 Solid Tumors 71 Pivotal Clinical Trial 71 Gastrointestinal Stromal Tumors 71 Severe Asthma 71 Relapsed Multiple Myeloma 71 Patency 71 Multiple Myeloma Patients 71 Intravitreal 71 Patients Receiving 71 Chronic Hepatitis C 71 Acute Decompensated Heart Failure 71 Stent Thrombosis 71 FDA Approvals 71 Neoadjuvant Chemotherapy 71 Bare Metal Stent 71 Hepatotoxicity 71 Investigational Treatment 71 Septic Shock 71 Pivotal Phase III 71 Natalizumab 71 NAVISTAR R 71 Tumor Response 71 Improve Survival 71 Interferon beta 1a 71 Advanced Colorectal Cancer 71 Bare Metal Stents 71 Melphalan 71 Hormone Receptor Positive 71 Peginterferon 71 Endarterectomy 71 Cardiovascular Events 71 dual endothelin receptor antagonist 71 Randomized Phase 71 Localized Prostate Cancer 71 Tolerability 71 Adjuvant Treatment 71 Metastatic Renal Cell Carcinoma 71 Fondaparinux 71 Double Blind Placebo 71 Post Operative 71 Decitabine 71 Allergic Rhinitis 71 Adjuvant Chemotherapy 71 Gastric Cancer 71 Oral Mucositis 71 Patient Outcomes 71 Tezampanel 71 Pivotal Phase 71 Phase 2a Clinical Trial 71 Drug Eluting 71 Hepatocellular Carcinoma 71 Treated Patients 71 Randomized Double blind 71 Breast Cancer Recurrence 71 Mycophenolate Mofetil 71 Diabetic Patients 71 Carotid Endarterectomy 71 Bosutinib 71 Pivotal Study 71 Knee Osteoarthritis 71 Stent Implantation 70 Hemodialysis Patients 70 Decompensated Heart Failure 70 Phase IIb Clinical Trial 70 ARIXTRA R 70 Aliskiren 70 riociguat 70 Diabetic Macular Edema 70 TAXUS ATLAS 70 NDA Submission 70 ritonavir boosted 70 Colorectal Cancer Patients 70 Combination Therapy 70 Previously Treated 70 ACTEMRA TM 70 Fracture Risk 70 Pharmacokinetics PK 70 Insulin Therapy 70 Val HeFT 70 Shows Promise Against 70 Myocardial Infarction Study 70 Phase III Clinical Trials 70 Improved Survival 70 Single Dose 70 Replacement Therapy 70 Bivalirudin 70 Investigational Compound 70 Lacosamide 70 HCV Protease Inhibitor 70 Reduces Mortality 70 Secondary Hyperparathyroidism 70 Chronic Myeloid Leukemia 70 Demonstrates Significant 70 PEG IFN 70 Phase Ib Clinical Trial 70 Golimumab 70 Randomized Study 70 Left Ventricular Dysfunction 70 Ischemic 70 Randomized Controlled Trials 70 Acute Myocardial 70 Myocardial Infarction 70 Eluting Stent 70 Venous Thrombosis 70 Chronic Hepatitis B 70 Diabetic Neuropathy 70 Versus Placebo 70 Adalimumab 70 Shows Efficacy 70 Myocardial Ischemia 70 Statin Therapy 70 Interferon Beta 70 Aneurysm Repair 70 Appears Safe 70 Renal Function 70 Relapsing Remitting Multiple Sclerosis 70 Metastatic Melanoma 70 First Patient Dosed 70 Castration Resistant Prostate Cancer 70 Investigational Drug 70 Fungal Infections 70 Anticoagulation 70 Intracerebral Hemorrhage 70 Cutaneous T 70 Chronic Renal Failure 70 Initiate Clinical Trial 70 Drug Shows Promise 70 Phase 2b Trial 70 Nesiritide 70 First Patient Treated 70 Renal Artery 70 Lupus Nephritis 70 Refractory Angina 70 Efficacy Trial 70 Completes Patient Enrollment 69 Treatment Naïve 69 Infarction 69 Dupuytren Contracture 69 Adjunctive Therapy 69 Prospective Randomized Trial 69 Orally Active 69 FDA APPROVES 69 Percutaneous Tibial Nerve Stimulation 69 Acute Coronary Syndrome 69 Unresectable 69 Completes Enrollment 69 Risk Stratification 69 Pegylated Interferon 69 Pediatric Patients 69 Advanced Prostate Cancer 69 Skeletal Muscle 69 Phase IIa Clinical Trial 69 Thrombotic 69 vapreotide acetate 69 Premature Infants 69 Previously Untreated 69 Treatment Regimen 69 APTIVUS 69 Cell Lymphoma 69 Multicenter 69 STRIDE PD 69 Soft Tissue Sarcoma 69 CCX# B 69 Diabetic Nephropathy 69 Myelofibrosis 69 Systemic Sclerosis 69 Atypical Hemolytic Uremic Syndrome 69 Minimally Invasive Treatment 69 Preclinical Data 69 alfa 2a 69 Chronic Sinusitis 69 Renal Impairment 69 Cardiac Resynchronization Therapy 69 Treatment Naive Patients 69 Clinical Efficacy 69 Statistically Significant 69 ST Segment Elevation 69 Proves Effective 69 Randomized Double Blind 69 Plaque Psoriasis 69 Eculizumab 69 Therapy Reduces 69 Anti Tumor Activity 69 Intravascular 69 Hypertensive Patients 69 Advanced Renal Cell 69 Cardiac Resynchronization 69 Multicenter Randomized 69 Sustained Efficacy 69 Improve Outcomes 69 HER2 Positive Breast Cancer 69 Myeloma Patients 69 Endovascular Treatment 69 Zoledronic Acid 69 Receives Orphan Drug Designation 69 Renal Cancer 69 Low Dose 69 Nilotinib 69 Thromboembolism 69 Cardiovascular Outcomes 69 Adjunctive 69 Double Blind Randomized 69 Multicenter Study 69 Naive Patients 69 Drug Candidate 69 clevidipine 69 CYT# potent vascular disrupting 69 Clinical Evaluation 69 Degarelix 69 ACE Inhibitors 69 Phase III Trials 69 Benign Prostatic Hyperplasia 69 Progenitor Cells 69 Coronary Artery Bypass Graft 69 Mouse Model 69 Resistant Hypertension 69 Prophylactic Treatment 69 Dose Ranging Study 69 Anticancer Activity 69 MGd 69 Lung Cancer Trial 69 Total Knee Arthroplasty 69 Postmenopausal Women 69 evaluating tivozanib 69 Investigational Agent 69 ZOLINZA 69 Randomized Controlled Trial 69 Initiate Phase 69 Fixed Dose 69 Ventricular Arrhythmias 69 Serious Infections 69 Diabetic Neuropathic Pain 69 Randomized Double Blind Placebo 69 Obese Patients 69 Shows Promising 69 Relapsed Refractory 69 Neoadjuvant 69 TO AVOID PREGNANCY WHILE 69 Demonstrated Significant 69 Endometrial Cancer 69 Aggressive Drug Evaluation 69 Partial Onset Seizures 69 MR Angiography 69 Patient Enrollment 69 Pertuzumab 69 Bone Metastases 69 Mitral Regurgitation 69 Malignant Melanoma 69 Phase III Pivotal 68 Clostridium difficile Infection 68 Chronic Bronchitis 68 Hypercholesterolemia 68 Prostate Cancer Patients 68 Diabetic Foot Ulcer 68 Sirolimus Eluting Stent 68 Antiplatelet Therapy 68 APTIVUS r 68 Coronary Stent 68 Patients Suffering 68 First Patient Enrolled 68 oral prodrug 68 Recurrent Breast Cancer 68 Lupus Drug 68 IND Filing 68 Treatment Reduces 68 Ozarelix 68 Randomized Clinical Trials 68 Treatment Outcome 68 ORENCIA ® 68 Epratuzumab 68 Symptom Relief 68 Lung Injury 68 Allogeneic 68 Placebo Controlled Study 68 Androgen Deprivation Therapy 68 Laryngeal Cancer 68 hyperphenylalaninemia HPA due 68 MEK Inhibitor 68 Breast Density 68 PEGINTRON TM 68 Clinical Outcomes 68 Intravesical 68 Stenting 68 Multicenter Trial 68 Intracranial Aneurysms 68 Infected Patients 68 Estrogen Therapy 68 Angiographic 68 Denufosol 68 Darunavir 68 Lenalidomide 68 Inhaled Corticosteroids 68 Angioedema 68 Breast Cancer Treatment 68 Malignant Glioma 68 Primary Hypercholesterolemia 68 Metabolic Efficiency 68 Cognitive Function 68 Major Depressive Disorder 68 RNAi Therapeutic 68 Antiviral Therapy 68 FOLOTYN ® 68 INVEGA ® 68 Radical Prostatectomy 68 colesevelam HCl 68 Anthracycline 68 Myocardial Perfusion Imaging 68 Medoxomil 68 Proven Effective 68 Tacrolimus 68 SUTENT ® 68 Restenosis 68 Renal Anemia 68 Preclinical Study 68 Endeavor Drug Eluting 68 Protease Inhibitor 68 Advanced Solid Tumors 68 Sanvar R 68 Achieves Primary Endpoint 68 Phase 2a Trial 68 Intra Arterial 68 Randomized Trials 68 Fabry Disease 68 Pafuramidine 68 Trial Evaluating 68 Antipsychotic 68 Drug Eluting Stent System 68 Long Term Outcomes 68 Coronary Angiography 68 Dendritic Cells 68 Potent Antiviral Activity 68 Fulvestrant 68 Mg Usa 68 Contrast Agents 68 Brain Metastases 68 Inhaled Nitric Oxide 68 Randomized Phase II 68 Combination REOLYSIN R 68 Left Ventricular Hypertrophy 68 Multicenter Phase 68 Dasatinib 68 Cilostazol 68 TLK# 68 Seasonal Allergic Rhinitis 68 Bronchial Thermoplasty 68 Enoxaparin 68 Liver Failure 68 IL# PE#QQR 68 Prospective Multicenter 68 CIMZIA TM certolizumab pegol 68 Cognitive Impairment 68 Beta Blocker 68 Prognostic Value 68 Schizophrenia Treatment 68 Lamotrigine 68 Immunosuppression 68 Aortic Valve Replacement 68 Novel Mechanism 68 Transdermal Patch 68 BARACLUDE R 68 Known hypersensitivity 68 Cholesterol Lowering Drug 68 orally inhaled migraine 68 Peginterferon Alfa 2a 68 Therapy Improves 68 Advanced Pancreatic Cancer 68 Initiates Enrollment 68 EVIZON TM 68 Intervention Effectiveness 68 TM Drug Eluting 68 Malignancies 68 Bucindolol 68 IND Application 68 Thyroid Hormone 68 Cancer Patients Treated 68 Liver Metastases 68 Tigecycline 68 GOUT 68 Trastuzumab 68 Hyperlipidemia 68 R lenalidomide 68 Randomized Phase III 68 Clinical Trial Data 67 Microplasmin 67 Biolimus A9 67 Bipolar Depression 67 Central Retinal Vein 67 Cypher Sirolimus 67 Contrast Agent 67 Hepatitis C Virus 67 brand ciclesonide HFA 67 complement inhibitor eculizumab 67 ExTRACT TIMI 67 Immunosuppressant 67 Protease Inhibitors 67 Systolic Blood Pressure 67 Occlusive Disease 67 Drug Prevents 67 Randomized Comparison 67 Recombinant Human 67 Ischemia 67 Initiates Clinical 67 Node Positive 67 Therapeutic Efficacy 67 Neuroprotective Effects 67 Paclitaxel Eluting 67 Kinase Inhibitor 67 Budesonide 67 Stem Cell Treatment 67 Study Demonstrates 67 Initiates Clinical Trial 67 PICSO ® 67 Phase III Pivotal Trial 67 Neovascular AMD 67 Valvular Heart Disease 67 Ventricular Tachycardia 67 Kidney Transplant Patients 67 Osteoarthritis Patients 67 Anti Tumor 67 oral rivaroxaban 67 ribavirin USP 67 Sipuleucel T 67 Significantly Reduces 67 Myelodysplastic Syndrome MDS 67 Hypotension 67 docetaxel Taxotere ® 67 Granted Orphan Drug 67 Traficet EN 67 Etanercept 67 Kamada AAT 67 Nonalcoholic Steatohepatitis 67 Corticosteroid 67 Universal Flu Vaccine 67 doxorubicin docetaxel 67 5 Fluorouracil 67 ribavirin RBV 67 Inhalation Aerosol 67 Therapeutic Potential 67 Treatment Experienced 67 HDAC Inhibitor 67 Sirolimus eluting Coronary Stent 67 ATACAND 67 lexidronam injection 67 Carotid 67 Advanced Ovarian Cancer 67 RE LY ® 67 Polymerase Inhibitor 67 Aortic Dissection 67 Increased Mortality 67 Nymox NX 67 Nicotine Vaccine 67 Hsp# Inhibitor 67 Systolic Hypertension 67 Demonstrates Sustained 67 Alteplase 67 Adjuvant Breast Cancer 67 icatibant 67 CIMZIA TM 67 Kidney Function 67 Follicular Lymphoma 67 Critical Limb Ischemia 67 unfractionated heparin UFH 67 Bone Mineral Density 67 Bevacizumab 67 liposome injection 67 briakinumab 67 Parenteral Nutrition 67 Hematological Malignancies 67 failure ADHF 67 Recurrent Glioblastoma 67 Surgical Treatment 67 Treatment Resistant 67 Anticoagulant 67 Submits NDA 67 Demonstrates Potent 67 Tolvaptan 67 Heart Transplant Recipients 67 Ropinirole 67 Study Showed 67 Aggressive Reduction 67 Metabolic Disorder 67 Paroxysmal Atrial Fibrillation 67 Tanespimycin 67 Congestive Heart Failure 67 Emerging Therapies 67 Significantly Improved 67 Implantable Cardioverter Defibrillator 67 Reperfusion Injury 67 adalimumab Humira 67 Oral Formulation 67 Renal Cell Carcinoma RCC 67 Bioequivalence 67 Refractory Hodgkin Lymphoma 67 tumor lysis syndrome 67 Inflammatory Diseases 67 Aflibercept 67 Demonstrate Significant 67 Files IND 67 Acute Stroke 67 pan HDAC inhibitor 67 Renal Insufficiency 67 HuMax EGFr 67 Immunomedics Announces 67 Methylnaltrexone 67 Novel Antibiotic 67 Hormone Therapy 67 Edge STudy 67 Rotavirus Vaccine 67 Lubiprostone 67 Receptor Agonist 67 novel VDA molecule 67 Sirolimus Eluting 67 OMNARIS HFA 67 Efficacious 67 Overactive Bladder OAB 67 Initiates Phase III 67 Effectively Treats 67 Ziprasidone 67 Long Term Survival 67 LibiGel ® 67 ALN HPN 67 TMC# r 67 Hospital Acquired Pneumonia 67 Interferon Alpha 67 Androxal TM 67 CLINICAL PHARMACOLOGY 67 Romiplostim 67 Microwave Ablation System 67 Thrombolytic 67 Ancrod 67 Feasibility Trial 67 Lung Cancer Drug 67 Oral Spray 67 Critical Limb Ischemia CLI 67 miconazole Lauriad ® 67 Parathyroid Hormone 67 Non inferiority 67 Postmenopausal Osteoporosis 67 Complete Remission 67 Plus Ribavirin 67 metastatic malignant 67 Phase 2a Study 67 EURIDIS 67 Atopic Dermatitis 67 Cimzia ® certolizumab pegol 67 phase IIb trial 67 JAK2 Inhibitor 67 NSABP B 67 Initiated Phase 67 Combo Therapy 67 Fast Track Status 67 Antihypertensive 67 Intracranial 67 Albuferon TM 67 Mitoxantrone 67 Cardiometabolic 67 BENICAR HCT 67 Aortic Valve 67 Embolic Protection Device 67 Lung Cancer Patients 67 Zenvia Phase III 67 Pharmacokinetic 67 Predict Risk 67 Orphan Status 67 Recurrent Stroke 67 Thrombus 67 chemoradiation therapy 66 Xelox 66 Randomised 66 Ticagrelor 66 Present Preclinical Data 66 CT Angiography 66 antiplatelet agent 66 Systematic Review 66 Critically Ill Patients 66 Topline Results 66 Anti TNF 66 APTIVUS R 66 Capecitabine 66 ENDEAVOR IV 66 Blood Flow 66 INTEGRILIN R 66 Inhalation Solution 66 Patients Enrolled 66 Dapagliflozin 66 Inflammatory Markers 66 Receptor Antagonists 66 Non Responders 66 Peripheral Arterial 66 atypical Hemolytic Uremic Syndrome 66 Skin Lesions 66 Pivotal Trials 66 Randomized Controlled 66 ENDEAVOR II 66 Safety Tolerability 66 HepaSphere 66 recurrent glioma 66 Contrast Enhanced 66 CHAMPION PCI 66 Pemetrexed 66 Presents Preclinical Data 66 Interferon Gamma 66 Prostate Cancer Treatment 66 Presents Positive 66 Trandolapril 66 Neuroendocrine Tumors 66 AA Amyloidosis 66 FASLODEX 66 Mg Uk 66 Phase 1b Clinical Trial 66 Orthostatic Hypotension 66 alpha 2a 66 Iron Overload 66 rFVIIa 66 CIMZIA ™ 66 Sapacitabine 66 Immunotherapeutic 66 Active Rheumatoid Arthritis 66 Robotic Assisted 66 plasma kallikrein inhibitor 66 Vicriviroc 66 Diffuse Large B 66 Brentuximab Vedotin SGN 66 CYPHER R Sirolimus Eluting 66 Anti CD# Antibody 66 invasive candidiasis 66 Osteoporosis Treatment 66 Intrathecal 66 Efficacy Results 66 Anti VEGF 66 Prevent Stroke 66 Surgical Procedures 66 Demonstrates Potential 66 Vidaza azacitidine 66 Diabetic Macular Edema DME 66 Phase IIIb 66 Mimetics 66 rilonacept 66 Observational Study 66 Randomised Trial 66 Sleep Disturbances 66 Embolic 66 Outpatient Setting 66 Sandostatin R 66 THAT ARE DIFFICULT TO 66 Receptor Antagonist 66 Anticancer Drug 66 Liposomal 66 acute peripheral arterial 66 GW# [003] 66 CYPHER R Sirolimus eluting 66 J Am Coll 66 HER2 Positive 66 R Saizen R 66 Placebo Controlled 66 Microalbuminuria 66 TMS Therapy 66 cinacalcet 66 Medullary Thyroid Cancer 66 Blood Pressure Reduction 66 Targeted Therapy 66 placebo controlled clinical 66 J Clin 66 Inflammatory Arthritis 66 Autoimmune Disease 66 Ischaemic 66 Nucleoside 66 epoetin alpha 66 Progressive Multifocal Leukoencephalopathy 66 Hydroxyurea 66 Paroxysmal Nocturnal Hemoglobinuria PNH 66 pharmacokinetic PK study 66 Tumor Growth 66 Ventricular 66 Carotid Revascularization Endarterectomy vs. 66 somatostatin analog 66 Candesartan 66 unstable angina pectoris 66 Adenoma Prevention 66 Embolization 66 Cancer Therapies 66 Drug Eluting Stent 66 phase IIIb 66 Eluting Coronary Stent System 66 sunitinib Sutent 66 achieved CCyR 66 Valve Replacement 66 Pulmonary Artery 66 Aortic Aneurysm 66 alfuzosin 66 Adefovir 66 Non Inferiority 66 Lung Cancer Survival 66 PRADAXA 66 Oral Cladribine 66 Carboplatin Paclitaxel 66 Successfully Completes Phase 66 galiximab 66 Polyneuropathy 66 Cholesterol Levels SPARCL 66 including eniluracil ADH 66 Antiplatelet 66 pioglitazone HCl 66 imipramine Tofranil 66 Zorbtive TM 66 HFA MDI 66 Hematological 66 Intracoronary 66 Tumor Targeting 66 Coronary Artery Bypass Surgery 66 Confirmatory Phase 66 Prognostic Significance 66 sitaxsentan 66 Diastolic Heart Failure 66 Generalized Anxiety Disorder 66 Virus Infection 66 Echocardiographic 66 Suicidality 66 TMC# C# 66 Liver Injury 66 Glufosfamide 66 Helicobacter pylori eradication 66 Calcium Acetate 66 Confirms Efficacy 66 sertraline Zoloft 66 Occlusion 66 virological response 66 RE LY 66 biologic DMARD 66 AIR2 Trial 66 Tocilizumab 66 phase IIb clinical 66 Balloon Angioplasty 66 thalidomide Thalomid 66 candesartan cilexetil 66 Prostatectomy 66 COPERNICUS 66 rt PA 66 Tasimelteon 66 Tesamorelin 66 SEROQUEL R 66 samarium Sm 66 Immune Mediated 66 8mg/kg 66 Colorectal Adenomas 66 Interferon Alfa 66 Medication Adherence 66 Biphasic 66 Expanded Indication 66 Regimens 66 IN PATIENTS WITH 66 Oral Insulin 66 Liver Tumors 66 See WARNINGS 66 Rheumatoid 66 PHASE III 66 Extended Release 66 FOLFOX6 chemotherapy regimen 66 Non Invasive Treatment 66 recurrent glioblastoma multiforme 66 BrachySil TM 66 Cardiac Function 66 blinded randomized placebo controlled 66 LEUKINE 66 Fludara ® 66 Telithromycin 66 Insulin Resistance 66 Anti Clotting Drug 66 Invasive Fungal Infections 66 Dyslipidemia 66 diarrhea predominant irritable 66 Prostate Biopsy 66 Cyclosporine 66 oral antidiabetic medication 66 Elagolix 66 Chronic Constipation 66 Immunogenicity 66 Significantly Improves 66 Viral Suppression 66 brivaracetam 66 Antithrombin 66 Total Knee Replacement 66 either acutely decompensated 66 Osteoporosis Drug 66 FDA Approvable Letter 66 PROMUS TM 66 Navelbine ® 66 Fluticasone 66 Montelukast 66 Guidelines Issued 66 Depressive Symptoms 66 Preclinical Efficacy 66 PERSEUS 66 Tipranavir 66 Rheumatoid Arthritis RA 66 Hepatic 66 Virologic 66 Clinical Study Shows 66 TNF Tumor Necrosis Factor 66 Community Acquired Pneumonia 66 Certolizumab 66 Successfully Treated 66 undergoing elective percutaneous 66 Epidermal Growth Factor Receptor 66 sirolimus eluting stents 66 Omacetaxine 66 denileukin diftitox 66 Teduglutide 66 HCV SPRINT 66 Neovascular Age Related Macular 66 atazanavir sulfate 66 nicardipine 66 SPRYCEL ® 66 Fludarabine 65 lucinactant 65 STENT 65 Neulasta ® 65 prucalopride 65 cisplatin gemcitabine 65 Poster Presentations 65 PKC# 65 acetonide FA 65 Premenopausal Women 65 Drug Combo 65 Transcatheter 65 Cytotoxicity 65 certolizumab 65 Exacerbation 65 RENAL 65 relapsed MM 65 multicenter Phase III 65 Boosts Survival 65 Bosentan 65 Pulmonary Vein Isolation 65 Serdolect ® 65 liposomal doxorubicin 65 Adult Stem Cell Therapy 65 Bloodstream Infections 65 Ridaforolimus 65 Neuroprotection 65 venlafaxine Effexor 65 KRN# 65 CYP#A# CYP#D# 65 Ranibizumab 65 Gout Drug 65 LANTUS ® 65 Remission Maintenance 65 Catena ® 65 Dyloject TM 65 aripiprazole Abilify 65 Clinically Significant 65 Juvenile Idiopathic Arthritis 65 FDA Clearance 65 Successfully Treats 65 Respiratory Distress 65 Artery Disease 65 Disease Modifying 65 Insulin Glargine 65 Heterozygous Familial Hypercholesterolemia 65 erlotinib Tarceva ® 65 Tyrosine Kinase Inhibitors 65 ThermoDox R 65 Electrical Stimulation 65 Initiates Phase II 65 Hospitalized Patients 65 ISTODAX ® 65 ribavirin Copegus ® 65 Slows Progression 65 ULORIC 65 Mitral Valve Repair 65 FIRMAGON 65 Coronary Arteries 65 Clinical Relevance 65 Bazedoxifene 65 ORLive Presents 65 prospective multicenter study 65 Drug Eluting Coronary Stent 65 catheter occlusion 65 Epoetin Alfa 65 Dialysis Outcomes 65 VAPRISOL 65 Left Atrial 65 thrombus aspiration 65 MAGE A3 ASCI 65 Enzastaurin 65 familial amyloidotic polyneuropathy FAP 65 FOLFOX6 65 Cardiomyocytes 65 Prophylaxis 65 Less Invasive 65 Infliximab 65 CINQUIL 65 Molecular Weight Heparin 65 Phase Ib study 65 Ambulatory Blood Pressure 65 Alfimeprase 65 Investigational eFlow Nebulizer System 65 ARCOXIA 65 Circulating Tumor Cells 65 NATRECOR ®